All In Biotech

Drug Trial Radar · NCT00461630

Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE

A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant

Last checked: Nov 19, 2026Latest source record: Feb 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 25,673 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

25,673

Actual

Start

Jan 2007

Primary completion

Oct 2012

Study completion Oct 2012

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Merck Sharp & Dohme LLC
First posted
Apr 18, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary aim is to assess the effects of raising HDL cholesterol (the good type) with extended release niacin/laropiprant 2g (previously known as MK-0524A) versus matching placebo on the risk of heart attack or coronary death, stroke, or the need for arterial bypass procedures (revascularisation) in people with a history of circulatory problems. The secondary aim is to assess the effects of extended release niacin/laropiprant 2g daily on heart attack, coronary death, stroke, and revascularisation separately and to assess the effects on mortality both overall and in various categories of causes of death, and of the effects on major cardiovascular events in people with a history of different diseases at the beginning of the study.

Conditions

  • Cardiovascular Disease
  • Peripheral Arterial Disease
  • Diabetes Mellitus
  • Coronary Heart Disease

Interventions

  • ER niacin/laropiprantDrug

  • simvastatinDrug

    40 mg simvastatin tablet orally per day as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level

  • ezetimibe/simvastatinDrug

    10 mg ezetimibe plus 40 mg simvastatin in single tablet taken once daily as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Vascular EventTime frame: During scheduled treatment period (median duration 3.9 years)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Service Unit, University of Oxford

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.